Actively Recruiting
Perinatal Covid-19 Infection, NO Pathway, and Minipuberty
Led by University Hospital, Lille · Updated on 2023-02-08
180
Participants Needed
2
Research Sites
208 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Lille
Lead Sponsor
E
European Commission
Collaborating Sponsor
AI-Summary
What this Trial Is About
Some evidence exists that SARS-COV-2 may infect pituitary axis, and therefore may alter hypothalamic function. Whether perinatal COVID-19 is associated with alterations in the maturation of the Hypothalamic-Pituitary-Gonadal (HPG) axis, and specifically with its transient activation occurring during infancy, namely minipuberty, is a major concern. Among the various pathogenic features related to COVID-19, altered minipuberty could be a key factor underlying many multimorbidities later in life, suggesting that they could involve a common causative mechanism that occurs within this short and critical period of time following birth. Altered minipuberty together with NO deficiency seem to be key factors underlying many of these multimorbidities, suggesting that they involve a common causative mechanism that occurs within this short and critical period of time following birth
CONDITIONS
Official Title
Perinatal Covid-19 Infection, NO Pathway, and Minipuberty
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newborn infants born between 24 and 41 weeks gestation or young infants younger than 3 months admitted to the maternity ward or neonatal department
- Group 1: Infants with perinatal COVID-19 infection shown by positive PCR in the mother during pregnancy or in the infant after birth
- Group 2: Infants with severe cardiorespiratory disease requiring inhaled nitric oxide treatment
- Group 3: Control infants without COVID-19 infection or inhaled nitric oxide treatment, matched by birth age, postnatal age, and respiratory failure status
- No participation in another ante- or post-natal trial
- Written consent obtained from both parents
- Social security affiliation
You will not qualify if you...
- Birth before 24 weeks gestation
- Severe brain injuries such as extensive periventricular leukomalacia or grade 3 or 4 intracranial hemorrhage
- One or both parents unable to read or understand French or who refuse to participate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hop Jeanne de Flandre Chu Lille
Lille, France, 59037
Actively Recruiting
2
Uri-National and Kapodistrian University of Athens
Athens, Greece
Not Yet Recruiting
Research Team
L
Laurent STORME, MD,PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here